Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics (NYSE American: TOVX) reported Q2 2026 results and said first patients were dosed in the VIRAGE2 Phase 2a trial testing more frequent VCN-01 dosing in metastatic PDAC. The company reported $11.3M cash as of June 30, 2026. General and admin expenses fell to $2.0M and R&D to $1.3M.
How this was made
The 30-second read
Why it matters
The VIRAGE2 trial is designed to test feasibility and safety of at least three VCN-01 doses about two months apart with standard-of-care chemotherapy, with enrollment expected in 2H 2026 and initial data anticipated by Q3 2027. The company also reports Q2 2026 liquidity (cash $11.3M) and expense trends.
Market read
Traders get a fresh clinical execution datapoint (first patients dosed) and a near-term funding-risk check (cash runway into Q1 2027), which can influence biotech risk appetite and financing expectations.
What to watch
The cash runway is into Q1 2027, but the article does not quantify expected burn through VIRAGE2 enrollment completion in 2H 2026, which could affect financing expectations.
Background
Theriva Biologics is a clinical-stage oncology company developing VCN-01 (zabilugene almadenorepvec) across multiple indications, including metastatic pancreatic ductal adenocarcinoma (PDAC).
Ticker impact
Theriva Biologics reports first patient dosing in its VIRAGE2 Phase 2a trial for VCN-01 and provides Q2 2026 cash runway into Q1 2027.
Moderate positive bias, with upside skew if Q3 2027 safety/pharmacodynamic data expectations firm up and cash runway reduces dilution risk.
The article discloses a fresh clinical milestone (first patients dosed) plus balance-sheet liquidity (cash $11.3M as of June 30, 2026). However, it does not provide efficacy results or updated guidance that would likely drive a large immediate repricing.
Market effects
Adds incremental validation for oncolytic adenovirus plus immune checkpoint sequencing strategies in solid tumors, but impact is company-specific.
Limited, as the update is tied to a US-listed microcap and EU/US trial design discussions.
Low; no cross-company regulatory or partnership developments disclosed.
Counterpoint
First-patient dosing is an early operational milestone; without efficacy signals or updated funding plans, the market may discount it versus dilution risk.
Key entities
- issuerTheriva Biologics, Inc.
NYSE American-listed clinical-stage oncology company reporting Q2 2026 operational highlights and financial results.
- product_candidateVCN-01 (zabilugene almadenorepvec)
Oncolytic adenovirus therapy evaluated in VIRAGE2 for metastatic PDAC and in other oncology settings.
- clinical_programVIRAGE2 Phase 2a trial
Single-arm, open-label proof-of-concept study evaluating increased frequency repeated dosing of VCN-01 with gemcitabine/nab-paclitaxel.
- product_candidateSYN-004 (ribaxamase)
Program referenced in R&D expense discussion for Phase 1b/2a in allogeneic HCT recipients.
